



PRESS RELEASE
1 April 2022

Clinical Outcomes Solutions and FingerPost mark five years of collaboration dedicated to informing the COA Competitive Landscape in the anti-cancer therapy space

Clinical Outcomes Solutions ('COS'), a global leader in the collection, analysis and reporting of patient-centred outcomes data with offices in Folkestone (UK), and Tucson and Chicago (USA), today marks five years of partnering collaboratively with FingerPost, a leading consultancy providing market-specific payer and Health Technology Assessment (HTA) insights and intelligence worldwide.

Established in 2013, COS is a global leader in delivering innovative science to capture and communicate the patient voice, in order to provide actionable evidence in clinical drug development through qualitative and quantitative research, with a specific focus on Clinical Outcomes Assessments.

FingerPost is a leader in market access and pricing strategy, providing the expertise and critical capabilities for pharmaceutical companies to optimise launch success.

This long-standing partnership supports COS projects by providing specific insights relating to Clinical Outcomes Assessment data used for stakeholder decision-making. For COS clients, the significant benefit is that they are fully informed to consider not only the regulatory requirements for their COA strategy, but also the payer and HTA landscape, thereby informing and bolstering market access and laying the foundations for success. Clients also benefit from a single point of contact throughout.

Having completed over 30 reviews together since 2016, this partnership has already proven highly successful. The powerful combination of subject matter experts specialising in COA strategy, pricing, market access and reimbursement ensures COS clients benefit from the flexibility, efficiency and expertise of two niche agencies operating with a defined and highly developed methodology.

Stacie Hudgens, Chief Executive Officer at COS, said: "This scientific partnership between COS and Fingerpost is the culmination of a long-standing relationship dedicated to informing the COA Competitive Landscape for our Sponsor clients in the anti-cancer therapy space. Our equal passion and dedication to including and understanding the patient voice in outcomes and clinical research has led to evidence synthesis that truly informs the COA strategy in new drug development."

Catherine Bacon, Managing Director of FingerPost, said: ““Our partnership with COS has proven highly successful in delivering in depth analyses of Health Technology Assessments (HTA) and the impact of patient-relevant outcomes on reimbursement recommendations and value-based /managed entry agreements across numerous therapeutic areas. The trend of including PRO data in HTA submissions is ever increasing, particularly in oncology, where there are greater expectations from payers to demonstrate the benefits of new therapies beyond overall survival. Our structured and collaborative approach means that clients get the regulatory and market access expertise of two niche agencies, through one contract and one point of contact.”

Tara Symonds, Chief Science Officer at COS, said: “Our partnership with FingerPost allows Sponsors access to an even greater level of expertise. The depth of insight that this brings to any COA landscape analysis results in industry leading COA strategies for our clients to utilise in leveraging maximum value to key stakeholders. Like COS, FingerPost has a global reach and, importantly, shares our commitment not only to innovative science, but also in putting the patient at the heart of everything we do.”

-Ends-

Press Contacts

For more information, please contact:

clare@makeitdrive.co.uk

Notes to editors

About Clinical Outcome Solutions

Clinical Outcomes Solutions, founded in 2013, is a solution-focused team with global experience committed to bringing together the right team of experts to approach medical research questions. The expert team provides clients with the most effective clinical outcome solution to help make the right patient care value decisions. COS has expertise in qualitative and quantitative research that will result in actionable evidence to support clinical and regulatory strategies for both the US and European markets. For more information, please visit www.clinoutsolutions.com

About FingerPost Consulting Ltd

FingerPost, founded in 2015, is a specialist agency supporting pharmaceutical, biotech and medical device companies with Market Access and Pricing Strategy services. Over the past 6 years we have established a team of global healthcare experts covering 32 markets with Payer experts based in all major and mid-sized markets. We deliver solutions within market access, pricing, patient advocacy, policy, market research and Health Technology Assessment. The solutions provided by FingerPost across multiple disease areas and multiple geographies help clients to understand and address external challenges and support internal strategies to enable the best possible outcomes at launch. For more information, please visit www.fingerpostconsulting.com

